Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Transforming growth factor alpha (TGF-alpha) is a 50-amino acid polypeptide that belongs to the epidermal growth factor (EGF) family. It functions as a high-affinity ligand for the epidermal growth factor receptor (EGFR), stimulating receptor tyrosine kinase activity and subsequent signaling pathways (such as MAPK and PI3K/Akt) that promote cell proliferation, differentiation, and survival. While naturally occurring in the body, recombinant human TGF-alpha has been explored as a therapeutic agent for wound healing and gastrointestinal repair. In oncology, TGF-alpha is often overexpressed by cancer cells, contributing to autocrine growth stimulation and immune system evasion, as seen in pancreatic and head and neck cancers. In research settings, it is frequently used as a reagent to activate EGFR signaling in vitro.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on transforming growth factor alpha.